GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Price-to-Owner-Earnings

Ascendis Pharma A/S (Ascendis Pharma A/S) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 2015. Start your Free Trial

As of today (2024-04-16), Ascendis Pharma A/S's share price is $147.33. Ascendis Pharma A/S does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ascendis Pharma A/S's Price-to-Owner-Earnings or its related term are showing as below:


ASND's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.895
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-16), Ascendis Pharma A/S's share price is $147.33. Ascendis Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.21. Therefore, Ascendis Pharma A/S's PE Ratio for today is At Loss.

As of today (2024-04-16), Ascendis Pharma A/S's share price is $147.33. Ascendis Pharma A/S's EPS without NRI for the trailing twelve months (TTM) ended in was $-9.21. Therefore, Ascendis Pharma A/S's PE Ratio without NRI for today is At Loss.


Ascendis Pharma A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Ascendis Pharma A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Ascendis Pharma A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Price-to-Owner-Earnings falls into.



Ascendis Pharma A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ascendis Pharma A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=147.33/-10.80
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma A/S  (NAS:ASND) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ascendis Pharma A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (Ascendis Pharma A/S) Headlines